Rephine

Activities: Regulatory

Trending Articles

  1. Agilent boosts contract manufacturing capabilities with acquisition of BIOVECTRA The CDMO acquisition will bolster Agilent's end-to-end production capabilities in a number of popular therapeutics, including GLP-1 medications and ADCs
  2. Therapeutic: ensifentrine for chronic obstructive pulmonary disease Chronic obstructive pulmonary disease (COPD) comes in various guises, including chronic bronchitis and emphysema; and, although incurable, the symptoms can be managed with...
  3. Merck’s clesrovimab meets all primary endpoints in Phase IIb/III trial for RSV in infants A teaser of the Phase IIb/III trial released by Merck indicates that clesrovimab can reduce the need to medically attend lower respiratory infections caused by RSV in infants
  4. Bringing biotech to the Baltics: the rise of Lithuania Lithuania’s biotechnology competencies lie in cell and gene therapies, enzymes and the wider pharmaceutical industry, offering companies a rich pool of talent in a...
  5. Currax to build novel anti-obesity treatment production facility amidst GLP-1 supply issues The manufacturing facility will be dedicated to the production of anti-obesity drug Contrave, and will double its output in the EU and EEA

Upcoming event

ISPE Singapore

28-30 August 2024 | Conference and exhibition | Singapore See all

Related Content

Regulatory

How to comply with regulatory expectations to access compliance data for the entire pharmaceutical supply chain

The pharmaceutical supply chain must work and must be known, is not a novel idea. Anyone involved in this industry’s quality processes knows that mastering 100% of its supply chain has been unachievable in the current state-of-the-art… until now!
Regulatory

Five reasons why it is necessary to digitise supplier compliance information in pharma

Regulatory bodies have increased awareness about falsified drugs and subsequently worked out requirements to prevent falsified drugs entering the legal pharmaceutical supply chain.
Regulatory

Quality Risk Management explained

Rephine’s Roger Smith, Consultant and Auditor, explains in this new white paper
Regulatory

Rephine shares mantras for preparing a GMP audit in the COVID Era

Rephine’s Alessandro Manni, Consultant and Auditor, explains
Regulatory

White paper: Core Auditing Behaviours

Rephine's Roger Smith, Consultant and Auditor, explains
Regulatory

Rephine appoints Assistant General Manager for Regulatory Affairs

Bhavik Joshi’s experience covers initial Marketing Authorisation Application and Product Life-cycle Management for different countries like Europe, US, Canada and RoW market
Regulatory

Understanding investigations, root causes and implementing an effective CAPA system

Rephine's white paper is available to download now
Subscribe now